Case 02: Uterocervical cancer
Treatment Performed
“Combined immunotherapy for cancer” was performed for advanced cervical cancer refractory to standard therapies, by combining the cancer vaccine therapy (one course) and a drug to inhibit immunosuppression.
Treatment Outcome
Slight shrinkage of pelvic mass
Before treatment
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_01.png)
4 weeks after treatment initiation
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_02.png)
7 weeks after treatment initiation
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_03.png)
Amelioration of bilateral hydronephrosis
Before treatment
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_04.png)
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_05.png)
4 weeks after treatment initiation
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_06.png)
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_07.png)
7 weeks after treatment initiation
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_08.png)
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/08/02_09.png)
The tumor marker decreased
![](https://neoclinic-en.jp/wp/wp-content/uploads/2021/12/case02.png)